Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Net Income (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Net Income data on record, last reported at -$20.4 million in Q4 2025.

  • For Q4 2025, Net Income rose 41.1% year-over-year to -$20.4 million; the TTM value through Dec 2025 reached -$104.9 million, changed 0.42%, while the annual FY2025 figure was -$105.0 million, 0.33% changed from the prior year.
  • Net Income reached -$20.4 million in Q4 2025 per CCCC's latest filing, up from -$32.2 million in the prior quarter.
  • Across five years, Net Income topped out at -$15.7 million in Q4 2021 and bottomed at -$36.6 million in Q4 2022.
  • Average Net Income over 5 years is -$27.7 million, with a median of -$27.0 million recorded in 2022.
  • Peak YoY movement for Net Income: plummeted 133.64% in 2022, then soared 50.68% in 2024.
  • A 5-year view of Net Income shows it stood at -$15.7 million in 2021, then tumbled by 133.64% to -$36.6 million in 2022, then grew by 4.99% to -$34.8 million in 2023, then increased by 0.53% to -$34.6 million in 2024, then soared by 41.1% to -$20.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income were -$20.4 million in Q4 2025, -$32.2 million in Q3 2025, and -$26.0 million in Q2 2025.